# Ceva Inc: financial statements, quarterly

CEVA · Nasdaq · CIK 1173489 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ceva.md) · [Financials](/companies/ceva/financials.md) · [Filings](/companies/ceva/filings.md) · [Insiders](/companies/ceva/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ceva/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [24.1](/filings/0001437749-24-034218.md) | [24.2 d](/filings/0001437749-26-006091.md) | [22.1](/filings/0001437749-25-015509.md) | [28.4](/filings/0001437749-25-025932.md) | [27.2](/filings/0001437749-25-034103.md) | [29.2 d](/filings/0001437749-26-006091.md) | [24.2](/filings/0001437749-26-016119.md) | [25.7](/filings/0001437749-26-026774.md) | [28.4](/filings/0001437749-25-034103.md) | [31.3 d](/filings/0001437749-26-006091.md) | [27.0](/filings/0001437749-26-016119.md) | [29.0](/filings/0001437749-26-026774.md) |
| Cost of revenue | $m | [2.4](/filings/0001437749-24-034218.md) | [2.3 d](/filings/0001437749-26-006091.md) | [2.5](/filings/0001437749-25-015509.md) | [2.9](/filings/0001437749-25-025932.md) | [4.0](/filings/0001437749-25-034103.md) | [3.4 d](/filings/0001437749-26-006091.md) | [3.5](/filings/0001437749-26-016119.md) | [3.5](/filings/0001437749-26-026774.md) | [3.4](/filings/0001437749-25-034103.md) | [3.7 d](/filings/0001437749-26-006091.md) | [3.7](/filings/0001437749-26-016119.md) | [3.6](/filings/0001437749-26-026774.md) |
| Gross profit | $m | [21.7](/filings/0001437749-24-034218.md) | [21.9 d](/filings/0001437749-26-006091.md) | [19.6](/filings/0001437749-25-015509.md) | [25.5](/filings/0001437749-25-025932.md) | [23.2](/filings/0001437749-25-034103.md) | [25.9 d](/filings/0001437749-26-006091.md) | [20.8](/filings/0001437749-26-016119.md) | [22.1](/filings/0001437749-26-026774.md) | [25.0](/filings/0001437749-25-034103.md) | [27.6 d](/filings/0001437749-26-006091.md) | [23.3](/filings/0001437749-26-016119.md) | [25.4](/filings/0001437749-26-026774.md) |
| Research and development | $m | [17.8](/filings/0001437749-24-034218.md) | [18.1 d](/filings/0001437749-26-006091.md) | [18.0](/filings/0001437749-25-015509.md) | [18.8](/filings/0001437749-25-025932.md) | [18.0](/filings/0001437749-25-034103.md) | [16.9 d](/filings/0001437749-26-006091.md) | [17.6](/filings/0001437749-26-016119.md) | [18.8](/filings/0001437749-26-026774.md) | [19.5](/filings/0001437749-25-034103.md) | [18.9 d](/filings/0001437749-26-006091.md) | [19.8](/filings/0001437749-26-016119.md) | [19.3](/filings/0001437749-26-026774.md) |
| Operating income | $m | [(2.7)](/filings/0001437749-24-034218.md) | [(2.8) d](/filings/0001437749-26-006091.md) | [(5.0)](/filings/0001437749-25-015509.md) | [(0.0)](/filings/0001437749-25-025932.md) | [(2.6)](/filings/0001437749-25-034103.md) | [0.1 d](/filings/0001437749-26-006091.md) | [(4.4)](/filings/0001437749-26-016119.md) | [(4.5)](/filings/0001437749-26-026774.md) | [(2.1)](/filings/0001437749-25-034103.md) | [(0.4) d](/filings/0001437749-26-006091.md) | [(5.1)](/filings/0001437749-26-016119.md) | [(2.1)](/filings/0001437749-26-026774.md) |
| Income tax | $m | [1.1](/filings/0001437749-24-034218.md) | [7.2 d](/filings/0001437749-26-006091.md) | [1.7](/filings/0001437749-25-015509.md) | [1.6](/filings/0001437749-25-025932.md) | [1.0](/filings/0001437749-25-034103.md) | [1.7 d](/filings/0001437749-26-006091.md) | [1.0](/filings/0001437749-26-016119.md) | [1.1](/filings/0001437749-26-026774.md) | [1.7](/filings/0001437749-25-034103.md) | [2.2 d](/filings/0001437749-26-006091.md) | [1.3](/filings/0001437749-26-016119.md) | [1.8](/filings/0001437749-26-026774.md) |
| Net income | $m | [(5.0)](/filings/0001437749-24-034218.md) | [3.8 d](/filings/0001437749-26-006091.md) | [(5.4)](/filings/0001437749-25-015509.md) | [(0.3)](/filings/0001437749-25-025932.md) | [(1.3)](/filings/0001437749-25-034103.md) | [(1.7) d](/filings/0001437749-26-006091.md) | [(3.3)](/filings/0001437749-26-016119.md) | [(3.7)](/filings/0001437749-26-026774.md) | [(2.5)](/filings/0001437749-25-034103.md) | [(1.1) d](/filings/0001437749-26-006091.md) | [(4.5)](/filings/0001437749-26-016119.md) | [(2.9)](/filings/0001437749-26-026774.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.21)](/filings/0001437749-24-034218.md) | not reported | [(0.23)](/filings/0001437749-25-015509.md) | [(0.01)](/filings/0001437749-25-025932.md) | [(0.06)](/filings/0001437749-25-034103.md) | not reported | [(0.14)](/filings/0001437749-26-016119.md) | [(0.15)](/filings/0001437749-26-026774.md) | [(0.10)](/filings/0001437749-25-034103.md) | not reported | [(0.16)](/filings/0001437749-26-016119.md) | [(0.10)](/filings/0001437749-26-026774.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.1](/filings/0001437749-23-031089.md) | [23.3](/filings/0001437749-26-006091.md) | [21.2](/filings/0001437749-24-015687.md) | [24.7](/filings/0001437749-24-025558.md) | [13.2](/filings/0001437749-24-034218.md) | [18.5](/filings/0001437749-26-006091.md) | [18.8](/filings/0001437749-25-015509.md) | [29.1](/filings/0001437749-25-025932.md) | [17.3](/filings/0001437749-25-034103.md) | [40.6](/filings/0001437749-26-026774.md) | [21.4](/filings/0001437749-26-016119.md) | [44.3](/filings/0001437749-26-026774.md) |
| Current assets | $m | [171](/filings/0001437749-23-031089.md) | [209](/filings/0001437749-25-005523.md) | [206](/filings/0001437749-24-015687.md) | [207](/filings/0001437749-24-025558.md) | [211](/filings/0001437749-24-034218.md) | [216](/filings/0001437749-26-006091.md) | [217](/filings/0001437749-25-015509.md) | [209](/filings/0001437749-25-025932.md) | [214](/filings/0001437749-25-034103.md) | [285](/filings/0001437749-26-026774.md) | [281](/filings/0001437749-26-016119.md) | [283](/filings/0001437749-26-026774.md) |
| Total assets | $m | [296](/filings/0001437749-23-031089.md) | [304](/filings/0001437749-25-005523.md) | [301](/filings/0001437749-24-015687.md) | [300](/filings/0001437749-24-025558.md) | [305](/filings/0001437749-24-034218.md) | [309](/filings/0001437749-26-006091.md) | [310](/filings/0001437749-25-015509.md) | [303](/filings/0001437749-25-025932.md) | [306](/filings/0001437749-25-034103.md) | [388](/filings/0001437749-26-026774.md) | [388](/filings/0001437749-26-016119.md) | [392](/filings/0001437749-26-026774.md) |
| Current liabilities | $m | [25.7](/filings/0001437749-23-031089.md) | [26.9](/filings/0001437749-25-005523.md) | [26.8](/filings/0001437749-24-015687.md) | [25.0](/filings/0001437749-24-025558.md) | [27.7](/filings/0001437749-24-034218.md) | [30.5](/filings/0001437749-26-006091.md) | [29.1](/filings/0001437749-25-015509.md) | [24.3](/filings/0001437749-25-025932.md) | [24.7](/filings/0001437749-25-034103.md) | [28.7](/filings/0001437749-26-026774.md) | [27.4](/filings/0001437749-26-016119.md) | [28.0](/filings/0001437749-26-026774.md) |
| Shareholders' equity | $m | [257](/filings/0001437749-24-034218.md) | [264](/filings/0001437749-26-006091.md) | [262](/filings/0001437749-25-025932.md) | [264](/filings/0001437749-25-034103.md) | [266](/filings/0001437749-25-034103.md) | [267](/filings/0001437749-26-026774.md) | [269](/filings/0001437749-26-026774.md) | [266](/filings/0001437749-26-026774.md) | [269](/filings/0001437749-25-034103.md) | [336](/filings/0001437749-26-026774.md) | [338](/filings/0001437749-26-026774.md) | [340](/filings/0001437749-26-026774.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,281) d](/filings/0001437749-24-034218.md) | [4,813 d](/filings/0001437749-26-006091.md) | [(7,350)](/filings/0001437749-25-015509.md) | [2,380 d](/filings/0001437749-25-025932.md) | [399 d](/filings/0001437749-25-034103.md) | [8,042 d](/filings/0001437749-26-006091.md) | [(7,404)](/filings/0001437749-26-016119.md) | [1,183 d](/filings/0001437749-26-026774.md) | [(5,859) d](/filings/0001437749-25-034103.md) | [8,724 d](/filings/0001437749-26-006091.md) | [(4,885)](/filings/0001437749-26-016119.md) | [5,825 d](/filings/0001437749-26-026774.md) |
| Capital expenditure | $k | [892 d](/filings/0001437749-24-034218.md) | [761 d](/filings/0001437749-26-006091.md) | [904](/filings/0001437749-25-015509.md) | [608 d](/filings/0001437749-25-025932.md) | [414 d](/filings/0001437749-25-034103.md) | [1,029 d](/filings/0001437749-26-006091.md) | [311](/filings/0001437749-26-016119.md) | [691 d](/filings/0001437749-26-026774.md) | [426 d](/filings/0001437749-25-034103.md) | [1,493 d](/filings/0001437749-26-006091.md) | [2,315](/filings/0001437749-26-016119.md) | [634 d](/filings/0001437749-26-026774.md) |
| Share repurchases | $k | [3,003 d](/filings/0001437749-24-034218.md) | [3,160 d](/filings/0001437749-26-006091.md) | [1,278](/filings/0001437749-25-015509.md) | [1,998 d](/filings/0001437749-25-025932.md) | [4,180 d](/filings/0001437749-25-034103.md) | [1,000 d](/filings/0001437749-26-006091.md) | [0.0](/filings/0001437749-25-015509.md) | [6,162 d](/filings/0001437749-26-026774.md) | [988 d](/filings/0001437749-25-034103.md) | [0.0 d](/filings/0001437749-26-006091.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2019 (2019-09-30) | Q1 FY2020 (2020-03-31) | Q2 FY2020 (2020-06-30) | Q3 FY2020 (2020-09-30) | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.4](/filings/0001437749-20-022998.md) | [22.0](/filings/0001437749-21-011542.md) | [22.0](/filings/0001437749-21-019148.md) | [22.2](/filings/0001437749-21-025927.md) | [0.0](/filings/0001437749-22-011742.md) | [23.1](/filings/0001437749-22-019607.md) | [22.9](/filings/0001437749-22-026605.md) | [23.1](/filings/0001437749-23-013600.md) | [23.2](/filings/0001437749-23-022803.md) | [23.2](/filings/0001437749-22-026605.md) | [23.3](/filings/0001437749-23-013600.md) | [23.5](/filings/0001437749-23-022803.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,154,072 at 2026-08-04, from the cover of the [10-Q filed 2026-08-10](/filings/0001437749-26-026774.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.